{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T06:52:24Z","timestamp":1792047144481,"version":"4.4.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2017,3,2]],"date-time":"2017-03-02T00:00:00Z","timestamp":1488412800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Immunex, a wholly owned subsidiary of Amgen Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s00296-017-3679-4","type":"journal-article","created":{"date-parts":[[2017,3,2]],"date-time":"2017-03-02T03:07:25Z","timestamp":1488424045000},"page":"1075-1082","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Dose relationship between oral glucocorticoids and tumor necrosis factor inhibitors and the risk of hospitalized infectious events among patients with rheumatoid arthritis"],"prefix":"10.1007","volume":"37","author":[{"given":"Jennifer","family":"Schenfeld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Iles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil A.","family":"Accortt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,2]]},"reference":[{"issue":"9","key":"3679_CR1","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1002\/art.10524","volume":"46","author":"MF Doran","year":"2002","unstructured":"Doran MF, Crowson CS, Pond GR, O\u2019Fallon WM, Gabriel SE (2002) Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 46(9):2287\u20132293. doi:\n10.1002\/art.10524","journal-title":"Arthritis Rheum"},{"issue":"3","key":"3679_CR2","first-page":"387","volume":"35","author":"AL Smitten","year":"2008","unstructured":"Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA, Chan KA (2008) The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol 35(3):387\u2013393","journal-title":"J Rheumatol"},{"issue":"5","key":"3679_CR3","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1136\/ard.2010.128637","volume":"70","author":"K Au","year":"2011","unstructured":"Au K, Reed G, Curtis JR, Kremer JM, Greenberg JD, Strand V, Furst DE, Investigators C (2011) High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis 70(5):785\u2013791. doi:\n10.1136\/ard.2010.128637","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3679_CR4","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/rheumatology\/keq242","volume":"50","author":"JB Galloway","year":"2011","unstructured":"Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, Watson KD, Lunt M, Symmons DP, Consortium BCC, British Society for Rheumatology Biologics R (2011) Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 50 (1):124\u2013131. doi:\n10.1093\/rheumatology\/keq242","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"3679_CR5","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1093\/rheumatology\/kep325","volume":"49","author":"CG Grijalva","year":"2010","unstructured":"Grijalva CG, Kaltenbach L, Arbogast PG, Mitchel EF Jr, Griffin MR (2010) Initiation of rheumatoid arthritis treatments and the risk of serious infections. Rheumatology (Oxford) 49(1):82\u201390. doi:\n10.1093\/rheumatology\/kep325","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"3679_CR6","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1002\/acr.21805","volume":"64","author":"JR Curtis","year":"2012","unstructured":"Curtis JR, Xie F, Chen L, Muntner P, Grijalva CG, Spettell C, Fernandes J, McMahan RM, Baddley JW, Saag KG, Beukelman T, Delzell E (2012) Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus lower-risk rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 64(10):1480\u20131489. doi:\n10.1002\/acr.21805","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"7","key":"3679_CR7","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1002\/acr.22281","volume":"66","author":"JR Curtis","year":"2014","unstructured":"Curtis JR, Yang S, Patkar NM, Chen L, Singh JA, Cannon GW, Mikuls TR, Delzell E, Saag KG, Safford MM, DuVall S, Alexander K, Napalkov P, Winthrop KL, Burton MJ, Kamauu A, Baddley JW (2014) Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis. Arthritis Care Res (Hoboken) 66(7):990\u2013997. doi:\n10.1002\/acr.22281","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"3679_CR8","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.autrev.2012.06.008","volume":"12","author":"F Atzeni","year":"2012","unstructured":"Atzeni F, Sarzi-Puttini P, Botsios C, Carletto A, Cipriani P, Favalli EG, Frati E, Foschi V, Gasparini S, Giardina A, Gremese E, Iannone F, Sebastiani M, Ziglioli T, Biasi D, Ferri C, Galeazzi M, Gerli R, Giacomelli R, Gorla R, Govoni M, Lapadula G, Marchesoni A, Salaffi F, Punzi L, Triolo G, Ferraccioli G (2012) Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun Rev 12(2):225\u2013229. doi:\n10.1016\/j.autrev.2012.06.008","journal-title":"Autoimmun Rev"},{"issue":"2","key":"3679_CR9","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/MD.0b013e318211106a","volume":"90","author":"MA Lane","year":"2011","unstructured":"Lane MA, McDonald JR, Zeringue AL, Caplan L, Curtis JR, Ranganathan P, Eisen SA (2011) TNF-a antagonist use and risk of hospitalization for infection in a national cohort of veterans with rheumatoid arthritis. Medicine (Baltimore) 90(2):139\u2013145. doi:\n10.1097\/MD.0b013e318211106a","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"3679_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.39480","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges SL Jr., Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O\u2019Dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St Clair EW, Tindall E, Miller AS, McAlindon T (2016) 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 68 (1):1\u201326. doi:\n10.1002\/art.39480","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"3679_CR11","doi-asserted-by":"publisher","first-page":"e000078","DOI":"10.1136\/rmdopen-2015-000078","volume":"1","author":"B Haraoui","year":"2015","unstructured":"Haraoui B, Jovaisas A, Bensen WG, Faraawi R, Kelsall J, Dixit S, Rodrigues J, Sheriff M, Rampakakis E, Sampalis JS, Lehman AJ, Otawa S, Nantel F, Shawi M (2015) Use of corticosteroids in patients with rheumatoid arthritis treated with infliximab: treatment implications based on a real-world Canadian population. RMD Open 1 (1):e000078. doi:\n10.1136\/rmdopen-2015-000078","journal-title":"RMD Open"},{"issue":"4","key":"3679_CR12","doi-asserted-by":"publisher","first-page":"R139","DOI":"10.1186\/ar3453","volume":"13","author":"WG Dixon","year":"2011","unstructured":"Dixon WG, Suissa S, Hudson M (2011) The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses. Arthritis Res Ther 13(4):R139. doi:\n10.1186\/ar3453","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"3679_CR13","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1136\/ard.2011.151043","volume":"70","author":"A Strangfeld","year":"2011","unstructured":"Strangfeld A, Eveslage M, Schneider M, Bergerhausen HJ, Klopsch T, Zink A, Listing J (2011) Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis 70(11):1914\u20131920. doi:\n10.1136\/ard.2011.151043","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"3679_CR14","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1002\/art.34530","volume":"64","author":"CS Crowson","year":"2012","unstructured":"Crowson CS, Hoganson DD, Fitz-Gibbon PD, Matteson EL (2012) Development and validation of a risk score for serious infection in patients with rheumatoid arthritis. Arthritis Rheum 64(9):2847\u20132855. doi:\n10.1002\/art.34530","journal-title":"Arthritis Rheum"},{"issue":"6","key":"3679_CR15","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1136\/annrheumdis-2012-201338","volume":"72","author":"SA Dartel van","year":"2013","unstructured":"van Dartel SA, Fransen J, Kievit W, Flendrie M, den Broeder AA, Visser H, Hartkamp A, van de Laar MA, van Riel PL (2013) Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Ann Rheum Dis 72(6):895\u2013900. doi:\n10.1136\/annrheumdis-2012-201338","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-017-3679-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-017-3679-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-017-3679-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T08:20:18Z","timestamp":1498292418000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-017-3679-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,2]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["3679"],"URL":"https:\/\/doi.org\/10.1007\/s00296-017-3679-4","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,2]]}}}